Andrés José Maria Ferreri

43PUBLICATIONS
343CO-AUTHORS
Haematological tumoursImmunogenetics (incl. genetic immunology)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Aug 12, 2026
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

|Mar 29, 2026
Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

Luca Arcaini, Michele Merli, Sara Rattotti

|Mar 28, 2026
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Mar 15, 2026
Three-Hour Infusion of Methotrexate at 3 g/m2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS Risk.

Andrés J M Ferreri, Federico Erbella, Piera Angelillo

|Jan 10, 2026
High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry.

Bertrand Pourroy, Maria D Aumente, Christian Koenecke

|Dec 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent Lymphomas.

Michele Merli, Elisa Genuardi, Silvia Zibellini

Pageof 8

Frequent Collaborators

8 joint publications

Teresa Calimeri

5 joint publications

Ken Young

5 joint publications

Alessandra Tucci

5 joint publications

Emanuele Zucca